Comment on Matasar et al , page 499 Ofatumumab in diffuse large B cell lymphoma ?
暂无分享,去创建一个
[1] I. Lossos,et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. , 2013, Blood.
[2] N. Schmitz,et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Bingshu E. Chen,et al. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12 , 2012 .
[4] G. Salles,et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. , 2012, Blood.
[5] A. Hagenbeek,et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. , 2012, Blood.
[6] C. Gisselbrecht,et al. Relapses, treatments and new drugs. , 2012, Best practice & research. Clinical haematology.
[7] T. Molina,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.
[8] C. Gisselbrecht,et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. , 2010, Clinical lymphoma, myeloma & leukemia.
[9] A. Zelenetz,et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.